Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Initial Oral Vinorelbine Dosing Schedules Used for the Treatment of Advanced Non-small-cell Lung Cancer and Metastatic Breast Cancer in Clinical Routine in Germany and Austria (StepUp)

NCT02619929 is registered in ClinicalTrials.gov with Pierre Fabre Pharma GmbH as lead sponsor.

NCT NCT02619929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02619929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Initial Oral Vinorelbine Dosing Schedules Used for the Treatment of Advanced Non-small-cell Lung Cancer and Metastatic Breast Cancer in Clinical Routine in Germany and Austria (StepUp)
Lead sponsor
Pierre Fabre Pharma GmbH
Phase
Observational
Overall status
Completed
Start date
February 29, 2016
Completion date
March 31, 2018
Enrollment
108 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non-small-cell lung cancer